Flibanserin

• Post Date:

  Dec 07,2018

• Expiry Date:

  Jun 05,2019

• Detailed Description:

  Cas No. :167933-07-5 Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD).[2][3] The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three.[4][5] The certainty of the estimate is low.[4] The side effects of dizziness, sleepiness, and nausea occur about three to four times more often.[4]
  
  Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. Food and Drug Administration.[6] The rights to the drug were then transferred to Sprout Pharmaceuticals, which achieved approval of the drug by the US FDA in August 2015.[7]
  
  HSDD was recognized as a distinct sexual function disorder for more than 30 years, but was removed from the Diagnostic and Statistical Manual of Mental Disorders in 2013, and replaced with a new diagnosis called female sexual interest/arousal disorder (FSIAD).[8][9]
  

• CAS Registry Number:

  167933-07-5

• Synonyms:

  Bimt 17;3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one;1-(2-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one;1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one;

• Molecular Formula:

  C₂₀H₂₁F₃N₄O

• Molecular Weight:

  390.4021

• Molecular Structure:

  

• Company:

  Jinan Chenghishaungda Chemical Co.,LTD     [ China ]        

• Contact:

  Allen

• Tel:

  15689693073

• Fax:

  0531-58897032

• Email:

  3118607598@qq.com